Q1 Earnings Estimate for Revvity Issued By Leerink Partnrs

Revvity, Inc. (NYSE:RVTY) – Research analysts at Leerink Partnrs reduced their Q1 2025 earnings per share estimates for Revvity in a report released on Friday, November 22nd. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of $1.09 per share for the quarter, down from their prior forecast of $1.14. The consensus estimate for Revvity’s current full-year earnings is $4.85 per share. Leerink Partnrs also issued estimates for Revvity’s Q4 2025 earnings at $1.47 EPS.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.15. Revvity had a return on equity of 7.42% and a net margin of 9.34%. The firm had revenue of $684.10 million during the quarter, compared to the consensus estimate of $679.66 million. During the same period last year, the company earned $1.18 EPS. The company’s quarterly revenue was up 2.1% on a year-over-year basis.

A number of other equities analysts have also recently weighed in on RVTY. Leerink Partners increased their price objective on shares of Revvity from $130.00 to $135.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Wells Fargo & Company began coverage on Revvity in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $130.00 price target for the company. Barclays cut their price objective on Revvity from $140.00 to $135.00 and set an “overweight” rating on the stock in a report on Monday. TD Cowen raised their target price on Revvity from $141.00 to $144.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, Citigroup lifted their target price on Revvity from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Revvity currently has an average rating of “Moderate Buy” and an average price target of $131.73.

Revvity Price Performance

Shares of RVTY opened at $114.66 on Monday. The firm has a 50-day simple moving average of $120.37 and a two-hundred day simple moving average of $115.81. The stock has a market cap of $13.95 billion, a PE ratio of 55.39, a P/E/G ratio of 2.80 and a beta of 1.05. Revvity has a 1-year low of $86.30 and a 1-year high of $129.50. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.56 and a quick ratio of 2.97.

Revvity declared that its Board of Directors has initiated a stock repurchase program on Monday, November 4th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 6.5% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 7th. Investors of record on Friday, January 17th will be paid a $0.07 dividend. The ex-dividend date is Friday, January 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.24%. Revvity’s dividend payout ratio is currently 13.53%.

Insiders Place Their Bets

In other Revvity news, insider Tajinder S. Vohra sold 2,154 shares of the firm’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $121.73, for a total value of $262,206.42. Following the sale, the insider now directly owns 19,652 shares in the company, valued at $2,392,237.96. This trade represents a 9.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Tidal Investments LLC lifted its position in shares of Revvity by 2,388.8% during the 3rd quarter. Tidal Investments LLC now owns 52,787 shares of the company’s stock worth $6,744,000 after buying an additional 50,666 shares during the last quarter. Coldstream Capital Management Inc. grew its position in shares of Revvity by 5.1% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,247 shares of the company’s stock valued at $286,000 after buying an additional 110 shares during the last quarter. Geode Capital Management LLC raised its stake in Revvity by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 2,863,793 shares of the company’s stock worth $364,569,000 after acquiring an additional 25,078 shares in the last quarter. Guardian Wealth Management Inc. lifted its position in Revvity by 1.4% in the third quarter. Guardian Wealth Management Inc. now owns 11,796 shares of the company’s stock valued at $1,507,000 after acquiring an additional 158 shares during the last quarter. Finally, Continuum Advisory LLC lifted its position in Revvity by 2,972.7% in the third quarter. Continuum Advisory LLC now owns 338 shares of the company’s stock valued at $43,000 after acquiring an additional 327 shares during the last quarter. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.